TABLE 3.
Influence of immunosuppression and starting time of treatment on efficacy of FK463 in mouse models of disseminated candidiasis
Host condition | Starting time of treatment after infection (h) | Inoculum (CFU) | ED50 (mg/kg/day)a of:
|
||
---|---|---|---|---|---|
FK463 | FLCZ | AMPH-B | |||
Normal (untreated) | 1b | 1.9 × 106 | 0.13 (0.09–0.18) | 1.5 (1.10–2.15) | 0.04 (0.03–0.06) |
Hydrocortisone treated | 1b | 1.3 × 105 | 0.45 (0.32–0.64) | 14.9 (9.91–38.3) | 0.23 (0.16–0.32) |
Cyclophosphamide treated | 1b | 3.1 × 104 | 0.28 (NE) | ≥4.0d (NE) | 0.13 (NE) |
1b | 1.2 × 104 | 0.25 (NE) | 2.0 (1.40–2.85) | 0.07 (0.05–0.10) | |
24c | 1.2 × 104 | 0.32 (0.24–0.45) | 6.2 (4.49–8.43) | 0.21 (0.15–0.29) |
Values in parentheses are 95% confidence intervals. NE, confidence interval could not be estimated.
Once daily for 4 days, starting at 1 h after infection.
Once daily for 3 days, starting at 24 h after infection.
Fifty-percent survival was observed at 4.0 mg/kg of FLCZ.